Systematic review and meta‑analysis of Radix et Rhizoma Tripterygii Combined with dapagliflozin for diabetic nephropathy： efficacy and safety

ObjectiveTo systematically evaluate the efficacy and safety of Radix et Rhizoma Tripterygii–derived tripterygium glycosides （TG） combined with dapagliflozin for the treatment of diabetic kidney disease （DKD）.MethodsWe searched CNKI， VIP， Wanfang， CBM， PubMed， Embase， and the Cochrane Library from inception to December 31， 2024， for randomized controlled trials （RCTs） comparing TG plus dapagliflozin versus dapagliflozin alone in DKD patients. Meta‑analysis was performed using RevMan 5.4.ResultsSeven RCTs comprising 741 patients were included. Compared with dapagliflozin monotherapy， TG combined with dapagliflozin significantly increased overall clinical response rate （RR=1.31； 95%CI， 1.20⁃1.43； P